Orgenesis Stock Cash Flow From Operations
| ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Orgenesis fundamentals help investors to digest information that contributes to Orgenesis' financial success or failures. It also enables traders to predict the movement of Orgenesis OTC Stock. The fundamental analysis module provides a way to measure Orgenesis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orgenesis otc stock.
Orgenesis |
Orgenesis OTC Stock Cash Flow From Operations Analysis
Orgenesis' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Orgenesis Cash Flow From Operations | (14.84 M) |
Most of Orgenesis' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Orgenesis has (14.84 Million) in Cash Flow From Operations. This is 102.81% lower than that of the Biotechnology sector and 123.73% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 101.53% higher than that of the company.
Orgenesis Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in cash flow from operations category among its peers.
Orgenesis Fundamentals
| Return On Equity | -7.27 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (16.54) % | ||||
| Current Valuation | 23.01 M | ||||
| Shares Outstanding | 4.77 M | ||||
| Shares Owned By Insiders | 21.16 % | ||||
| Shares Owned By Institutions | 4.54 % | ||||
| Number Of Shares Shorted | 56.25 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 15.21 X | ||||
| Revenue | 530 K | ||||
| Gross Profit | 36.02 M | ||||
| EBITDA | (54.07 M) | ||||
| Net Income | (64.92 M) | ||||
| Cash And Equivalents | 2.3 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 22.62 M | ||||
| Debt To Equity | 0.64 % | ||||
| Current Ratio | 1.57 X | ||||
| Book Value Per Share | (3.30) X | ||||
| Cash Flow From Operations | (14.84 M) | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | (8.00) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 146 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 10.07 M | ||||
| Total Asset | 14.55 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Working Capital | (12.33 M) | ||||
| Current Asset | 5.29 M | ||||
| Current Liabilities | 14.92 M | ||||
| Net Asset | 14.55 M |
About Orgenesis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orgenesis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |